PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser (fimaporfin) and a light source; and develops photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities, as well as photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing. It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases. In addition, the company develops fimaVACC for immunotherapy indications, which is in pre-clinical study; fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study for bioprocessing and dermatology indications; and technology for viral vector manufacturing and pre-clinical research for intratumoural immunotherapy. PCI Biotech Holding ASA was incorporated in 2007 and is headquartered in Oslo, Norway.
तुलना करने के लिए मीट्रिक्स | PCIBNOK | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPCIBNOKपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 0.0x | −2.0x | −0.6x | |
PEG अनुपात | 0.00 | −0.02 | 0.00 | |
क़ीमत/बुक | 0.0x | 2.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 9.6x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 210.1% | 56.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 18.4% | 7.8% | अनलॉक करें |